Expect Tazobactum approval by June 07: Orchid Chem


Orchid Chemicals has filed for European marketing approval For Tazobactum injectables.

K Raghavendra Rao, managing director, Orchid Chemicals and Pharma, expects the approval for Tazobactum sometime by June 2007, while the product patent is expiring in Europe for this product in July 2007. "So we expect to be in the market on day one with this product," he says.

Rao also expects very little competition because of the complexity of manufacturing Tazabactum. He further says that the product has got around $200 million-market originator in Western Europe. "So with very limited generic players, the pricing and profitability should be extremely good for this product from Europe," he says.CNBC-TV18 shares with domain-b its exclusive interview with Rao:

Tazobactum is the product in focus now. When are you likely to receive this European marketing approval?
We have filed this under a new procedure, where we filed this application simultaneously in 14 countries last month. There is a deadline within the European law, which has to give the approval within 300 days, provided all the documentations and inspections are in good order.

So we expect the approval sometime by June 2007 and the product patent is expiring in Europe for this product in July 2007. So we expect to be in the market on day one with this product.